Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a potential best-in-class, first line topical treatment for inflammatory skin diseases such as acne, atopic […]